Abstract:Hemorrhagic fever with renal syndrome (HFRS) occurs widely throughout Eurasia. Unfortunately, there is no effective treatment, and prophylaxis remains the best option against the major pathogenic agent, hantaan virus (HTNV), which is an Old World hantavirus. However, the absence of cellular immune responses and immunological memory hampers acceptance of the current inactivated HFRS vaccine. Previous studies revealed that a lysosome-associated membrane protein 1 (LAMP1)-targeting strategy involving a DNA vaccine based on the HTNV glycoprotein Gn successfully conferred long-term immunity, and indicated that further research on Gc, another HTNV antigen, was warranted. Plasmids encoding Gc and lysosome-targeted Gc, designated pVAX-Gc and pVAX-LAMP/Gc, respectively, were constructed. Proteins of interest were identified by fluorescence microscopy following cell line transfection. Five groups of 20 female BALB/c mice were subjected to the following inoculations: inactivated HTNV vaccine, pVAX-LAMP/Gc, pVAX-Gc, and, as the negative controls, pVAX-LAMP or the blank vector pVAX1. Humoral and cellular immunity were assessed by enzyme-linked immunosorbent assays (ELISAs) and 15-mer peptide enzyme-linked immunospot (ELISpot) epitope mapping assays. Repeated immunization with pVAX-LAMP/Gc enhanced adaptive immune responses, as demonstrated by the specific and neutralizing antibody titers and increased IFN-γ production. The inactivated vaccine induced a comparable humoral reaction, but the negative controls only elicited insignificant responses. Using a mouse model of HTNV challenge, the in vivo protection conferred by the inactivated vaccine and Gc-based constructs (with/without LAMP recombination) was confirmed. Evidence of pan-epitope reactions highlighted the long-term cellular response to the LAMP-targeting strategy, and histological observations indicated the safety of the LAMP-targeting vaccines. The long-term protective immune responses induced by pVAX-LAMP/Gc may be due to the advantage afforded by lysosomal targeting after exogenous antigen processing initiation and major histocompatibility complex (MHC) class II antigen presentation trafficking. MHC II-restricted antigen recognition effectively primes HTNV-specific CD4+ T-cells, leading to the promotion of significant immune responses and immunological memory. An epitope-spreading phenomenon was observed, which mirrors the previous result from the Gn study, in which the dominant IFN-γ-responsive hot-spot epitopes were shared between HLA-II and H2d. Importantly, the pan-epitope reaction to Gc indicated that Gc should be with potential for use in further hantavirus DNA vaccine investigations.

Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1/Kb transgenic mice

Screening and Identification of an H-2Kb-Restricted CTL Epitope Within the Glycoprotein of Hantaan Virus

Structure and Function of HLA-A*02-Restricted Hantaan Virus Cytotoxic T-Cell Epitope That Mediates Effective Protective Responses in HLA-A2.1/Kb Transgenic Mice

HLA-A2 and B35 Restricted Hantaan Virus Nucleoprotein CD8+ T-cell Epitope-Specific Immune Response Correlates with Milder Disease in Hemorrhagic Fever with Renal Syndrome.

Hantavirus-like Particles Generated in CHO Cells Induce Specific Immune Responses in C57BL/6 Mice

Integrative Analysis of HTNV Glycoprotein Derived MHC II Epitopes by <i>In Silico</i> Prediction and Experimental Validation

Comparative Immunoreactivity Analyses of Hantaan Virus Glycoprotein-Derived MHC-I Epitopes in Vaccination

Construction and Evaluation of DNA Vaccine Encoding Hantavirus Glycoprotein N-terminal Fused with Lysosome-Associated Membrane Protein.

A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of Hantaan virus induced protective immunity in mice

Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus

Pathogenicity of novel hantavirus isolate and antigenicity and immunogenicity of novel strain-based inactivated vaccine

Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles

Induction Of Hantaan Virus-Specific Immune Responses In C57bl/6 Mice By Immunization With A Modified Recombinant Adenovirus Containing The Chimeric Gene, Gcs0.7

DNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection

HLA Restricted CTL Epitope Mapping on Hantaan Virus Nucleocapsid Protein in China (128.7)

Construction and Immunological Characterization of CD40L or GM-CSF Incorporated Hantaan Virus Like Particle

Hantavirus Gc Induces Long-Term Immune Protection Via LAMP-targeting DNA Vaccine Strategy.

A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus

Immunogenicity of a Multi-Epitope DNA Vaccine Against Hantavirus.

Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune responses in C57BL/6 mice.

Induction Of Specific Humoral And Cellular Immune Responses In A Mouse Model Following Gene Fusion Of Hsp70c And Hantaan Virus Gn And S0.7 In An Adenoviral Vector